Gold Nanoparticles Bearing Functional Anti-Cancer Drug and Anti-Angiogenic Agent: A "2 in 1" System with Potential Application in Cancer Therapeutics

2005 ◽  
Vol 1 (2) ◽  
pp. 224-228 ◽  
Author(s):  
Priyabrata Mukherjee ◽  
Resham Bhattacharya ◽  
Debabrata Mukhopadhyay
Keyword(s):  
Gold Nanoparticles ◽  
Potential Application ◽  
Cancer Therapeutics ◽  
Cancer Drug ◽  
Anti Cancer

scholarly journals Peptide-functionalized gold nanoparticles: versatile biomaterials for diagnostic and therapeutic applications

2017 ◽  
Vol 5 (5) ◽  
pp. 872-886 ◽  
Author(s):  
Jingyi Zong ◽  
Steven L. Cobb ◽  
Neil R. Cameron
Keyword(s):  
Drug Delivery ◽  
Gold Nanoparticles ◽  
Targeted Drug Delivery ◽  
Potential Application ◽  
Cancer Therapeutics ◽  
Therapeutic Applications ◽  
Functionalized Gold Nanoparticles ◽  
Anti Cancer ◽  
Targeted Drug ◽  
Oligonucleotide Delivery

This review provides an overview of the current methods used for preparing peptide-functionalized GNPs, and discusses the key properties of this class of biomaterial. In particular, their potential application in areas of sensing, targeted drug delivery, anti-cancer therapeutics and oligonucleotide delivery are discussed.

scholarly journals Surface-Initiated Atom Transfer Polymerized Anionic Corona on Gold Nanoparticles for Anti-Cancer Therapy

Pharmaceutics ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 261
Author(s):  
Wei Mao ◽  
Sol Lee ◽  
Ji Un Shin ◽  
Hyuk Sang Yoo
Keyword(s):  
Gold Nanoparticles ◽  
Transfection Efficiency ◽  
Cancer Therapeutics ◽  
Atom Transfer ◽  
Layer By Layer ◽  
Dependent Manner ◽  
Metallic Particles ◽  
Anti Cancer

Surface initiated atom transfer radical polymerization (SI-ATRP) documented a simple but efficient technique to grow a dense polymer layer on any surface. Gold nanoparticles (AuNPs) give a broad surface to immobilize sulfhyryl group-containing initiators for SI-ATRP; in addition, AuNPs are the major nanoparticulate carriers for delivery of anti-cancer therapeutics, since they are biocompatible and bioinert. In this work, AuNPs with a disulfide initiator were polymerized with sulfoethyl methacrylate by SI-ATRP to decorate the particles with anionic corona, and branched polyethyeleneimine (PEI) and siRNA were sequentially layered onto the anionic corona of AuNP by electrostatic interaction. The in vitro anti-cancer effect confirmed that AuNP with anionic corona showed higher degrees of apoptosis as well as suppression of the oncogene expression in a siRNA dose-dependent manner. The in vivo study of tumor-bearing nude mice revealed that mice treated with c-Myc siRNA-incorporated AuNPs showed dramatically decreased tumor size in comparison to those with free siRNA for 4 weeks. Furthermore, histological examination and gene expression study revealed that the decorated AuNP significantly suppressed c-Myc expression. Thus, we envision that the layer-by-layer assembly on the anionic brushes can be potentially used to incorporate nucleic acids onto metallic particles with high transfection efficiency.

Synthesis of Polynucleotide Modified Gold Nanoparticles as a High Potent Anti-Cancer Drug Carrier

2009 ◽  
Vol 56 (4) ◽  
pp. 703-708 ◽  
Author(s):  
Ching-Ming Wu ◽  
Ping-Ching Wu ◽  
Yun-Han Wang ◽  
Tsung-Ju Li ◽  
Li-Xing Yang ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Drug Carrier ◽  
Cancer Drug ◽  
Anti Cancer

Cyclodextrin-covered gold nanoparticles for targeted delivery of an anti-cancer drug

2009 ◽  
Vol 19 (16) ◽  
pp. 2310 ◽  
Author(s):  
Chiyoung Park ◽  
Hyewon Youn ◽  
Hana Kim ◽  
Taiho Noh ◽  
Yeon Hee Kook ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Targeted Delivery ◽  
Cancer Drug ◽  
Anti Cancer

scholarly journals Nuclear targeting of gold nanoparticles

2021 ◽  
Author(s):  
Celina Yang
Keyword(s):  
Cancer Research ◽  
Gold Nanoparticles ◽  
Therapy Response ◽  
Drug Carriers ◽  
Treatment Modalities ◽  
Cancer Drug ◽  
Nuclear Targeting ◽  
The Third ◽  
The Past ◽  
Anti Cancer

Gold nanoparticles (GNPs) have been extensively used in cancer research due to their abilities as anti-cancer drug carriers for chemotherapy and as dose enhancers in radiotherapy. Although most GNP research in the past involved cytoplasm localized GNPs, it is predicted that therapy response can be enhanced if GNPs can be effectively targeted into the nucleus. A strategy for designing a GNP-peptide complex for targeting the nucleus will be presented. Three different sequences of peptides (CKKKKKKGGAGDMFG, CGGRKKRRGRRRAP, CALNN) were conjugated onto GNPs. The first peptide was used to stabilize the complex, the second peptide to enhance uptake into the cell, while the third peptide was used to induce nuclear delivery. With nuclear targeting, more damage can be caused to the DNP of cancer cells upon irradiation. This research will establish a more successful NP-based platform that combines treatment modalities and more effectively approach cancer treatment.

scholarly journals Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 1024 ◽  
Author(s):  
Jung-Eun Park ◽  
David Hymel ◽  
Terrence R. Burke, Jr. ◽  
Kyung S. Lee
Keyword(s):  
Side Effects ◽  
Cancer Therapeutics ◽  
Current Status ◽  
Cancer Drug ◽  
Mitotic Progression ◽  
Cancer Drug Discovery ◽  
Anti Cancer ◽  
Tumor Specificity ◽  
The Subject ◽  
New Generation

Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.

Gold nanospheres and nanorods for anti-cancer therapy: comparative studies of fabrication, surface-decoration, and anti-cancer treatments

Nanoscale ◽  
2020 ◽  
Vol 12 (28) ◽  
pp. 14996-15020
Author(s):  
Wei Mao ◽  
Young Ju Son ◽  
Hyuk Sang Yoo
Keyword(s):  
Gold Nanoparticles ◽  
Cancer Therapy ◽  
Cancer Therapeutics ◽  
Drug Carriers ◽  
Gold Nanospheres ◽  
Cancer Treatments ◽  
Anti Cancer ◽  
Diagnostic Agents ◽  
Irradiation Therapy ◽  
Surface Decoration

Various gold nanoparticles have been explored as cancer therapeutics because they can be widely engineered for use as efficient drug carriers and diagnostic agents, and in photo-irradiation therapy.

Triple function nanocomposites of porous silica-CoFe2O4-MWCNTs as a carrier for pH-sensitive anti-cancer drug controlled delivery

2017 ◽  
Vol 46 (43) ◽  
pp. 14831-14838 ◽  
Author(s):  
Huitao Fan ◽  
Xiaojing Xing ◽  
Yuhan Yang ◽  
Bo Li ◽  
Congcong Wang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Potential Application ◽  
Porous Silica ◽  
Ph Sensitive ◽  
Controlled Delivery ◽  
Cancer Drug ◽  
Targeted Cancer Therapy ◽  
Anti Cancer

A novel nanocarrier based on MWCNTs@CoFe2O4@mSiO2 was proposed, and its potential application for targeted cancer therapy was highlighted.

Industry Watch

2009 ◽  
Vol 13 (06) ◽  
pp. 36-54 ◽  
Keyword(s):  
H1n1 Virus ◽  
Digital Pathology ◽  
Cancer Therapeutics ◽  
Strategic Partnership ◽  
Cancer Drug ◽  
Purchase Order ◽  
Republic Of China ◽  
Drug Candidates ◽  
Anti Cancer ◽  
Stem Cell Treatment

"Off-The-Shelf" Stem Cell Treatment for Heart Failure. Cytopia Cancer Program Reaches Important Milestone at Cancer Therapeutics CRC. Starpharma and Elanco Agree to Develop New Products. China Sky One Medical, Inc. Achieves Significant Breakthrough In Sudden Cardiac Death (SCD) Early Examination Kit. Roche Applied Science Opens Application Support Center in Shanghai. Luminex Expands Globally and Opens Facility in People's Republic of China. Genesis Pharmaceuticals Launches Three New TCM Products. China Sky One Medical, Inc. to Develop New Anti-Cancer Drug with Taiwan Golden Biotechnology Corp. Solvay Pharmaceuticals Announces Strategic Partnership with HUYA to Access New Drug Candidates From China. Sinovac Receives $US12.9 mn Purchase Order for Healive® from China's Ministry of Public Health. GE Launches Lullaby Warmer for Newborn in India. SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore. Aperio Expands Global Digital Pathology Presence with New Subsidiary in Asia. Valeant Pharmaceuticals Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange. Genome Institute of Singapore and Roche NimbleGen Develop Rapid Approach to Identify H1N1 Virus Mutations and Resistance to Drugs.

scholarly journals Xyloglucan nano-aggregates: Physico-chemical characterisation in buffer solution and potential application as a carrier for camptothecin, an anti-cancer drug

2010 ◽  
Vol 82 (2) ◽  
pp. 355-362 ◽  
Author(s):  
Tatiane A. Jó ◽  
Denise F.S. Petri ◽  
Leila M. Beltramini ◽  
Neoli Lucyszyn ◽  
Maria Rita Sierakowski
Keyword(s):  
Potential Application ◽  
Cancer Drug ◽  
Buffer Solution ◽  
Physico Chemical ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document